Dimethyl Sulfoxide (DMSO) | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for Dimethyl Sulfoxide (DMSO), effective May 15, 2026. Here's what billing teams need to know before that date.

DMSO is one of those drugs that's been around for decades, but CMS coverage for it is narrow, specific, and easy to get wrong. The Centers for Medicare & Medicaid Services has updated its DMSO coverage policy, and if your practice or facility bills for this drug, you need to review your documentation and billing workflows before May 15, 2026. This policy does not list specific CPT or HCPCS codes in the available policy data — we'll cover what that means for your team below.

Quick-Reference Table

CMS Dimethyl Sulfoxide Coverage Criteria and Medical Necessity Requirements 2026

DMSO has exactly one FDA-approved indication: interstitial cystitis. That's been the anchor of the CMS DMSO coverage policy for years. Medicare covers DMSO when it's used as a bladder instillation for symptomatic relief of interstitial cystitis in patients who meet medical necessity criteria.

Medical necessity for DMSO under Medicare means the diagnosis must be documented, the treatment must be ordered by a physician, and the clinical record must support that other treatments have been tried or are not appropriate. Vague documentation won't hold up on audit. Your clinical notes need to directly tie the DMSO administration to the interstitial cystitis diagnosis.

Prior authorization is not universally required for DMSO under Medicare, but some Medicare Advantage plans do require prior auth. If your patients are on Medicare Advantage, check the specific plan's requirements before you bill — don't assume the fee-for-service rules apply.

The real issue with DMSO billing is that off-label use is common in clinical practice. Oncology teams use it as a cryoprotectant in stem cell transplants. Pain management providers use it topically. None of those uses are covered under the CMS DMSO coverage policy. CMS pays for interstitial cystitis treatment. Full stop.

Reimbursement for DMSO depends entirely on the site of service and how the drug is billed. Hospital outpatient departments bill it differently than physician offices. If you're billing under a Part B drug benefit, the drug must be administered incident-to or directly by the physician or their qualified staff. That administration requirement matters — it affects which codes you can use and whether the claim will pay.

CMS Dimethyl Sulfoxide Exclusions and Non-Covered Indications

CMS does not cover DMSO for off-label uses. That's the biggest exposure point for most billing teams.

Topical DMSO — often used in pain management or as a penetration enhancer for other drugs — is not a covered indication under Medicare. If your providers are ordering it for musculoskeletal pain, joint conditions, or as part of a compound, don't expect CMS to pay for it.

DMSO used as a cryoprotectant in stem cell or bone marrow transplant procedures is handled differently. In that context, the DMSO is typically bundled into the transplant procedure payment rather than billed separately as a standalone drug. Billing it separately in that context is a claim denial waiting to happen.

Investigational uses of DMSO — including any use in clinical trials outside the approved indication — are not covered under the standard coverage policy. If your facility is running trials involving DMSO, those claims follow a separate pathway entirely and should not be submitted under the standard drug benefit.

The pattern here is straightforward: if the diagnosis isn't interstitial cystitis, CMS is almost certainly not going to pay for DMSO. Your billing team needs to treat every DMSO claim as a medical necessity verification exercise.

Coverage Indications at a Glance

CMS Dimethyl Sulfoxide Billing Guidelines and Action Items 2026

This policy change takes effect May 15, 2026. Here's what your billing team should do before that date.

If you're uncertain how this modified policy applies to your specific patient mix or service lines, bring in your compliance officer before the effective date. The exposure here isn't catastrophic for most practices, but it's real — and it's avoidable.

CPT, HCPCS, and ICD-10 Codes for Dimethyl Sulfoxide Under This Policy

The policy data available for this CMS DMSO coverage policy update does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is unusual, and it matters for your billing team.

When a policy doesn't enumerate specific codes, that doesn't mean coding is free-form. It means you need to identify the correct codes based on:

• The site of service (physician office vs. hospital outpatient vs. ASC)
• How the drug is supplied and administered (instillation, infusion, topical)
• The applicable drug administration codes for your setting
• The HCPCS code for the DMSO drug itself, if billed separately

What to do: Contact your Medicare Administrative Contractor (MAC) to confirm which HCPCS code applies to DMSO in your billing context. Your MAC's local coverage determination (LCD) database may also have supplemental guidance. Don't assume a code is correct because it worked on past claims — confirm it against the updated policy.

The absence of specific codes in the policy data is itself a signal. It may mean coverage is determined by medical necessity criteria and diagnosis rather than by a code-specific coverage list. That makes diagnosis accuracy and documentation quality even more critical for every DMSO claim you submit.